Labetalol steady-state pharmacokinetics in hypertensive patients.
1 During chronic treatment of hypertensive patients observed mean steady-state plasma labetalol levels in ten patients were consistently and significantly higher than predicted from initial acute pharmacokinetic analysis. 2 Mean steady-state levels varied from 36 to 183 ng/ml on a chronic dose of 200 mg twice daily. 3 Patients with lower steady-state levels on a fixed dose of labetalol usually required higher maintenance doses to control blood pressure.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004983:Ethanolamines / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D007700:Kinetics; D007741:Labetalol / Q000097:blood* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D004983:Ethanolamines; D007741:Labetalol